Ligand Pharmaceuticals
LGND
259 hedge funds and large institutions have $2.5B invested in Ligand Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 109 increasing their positions, 91 reducing their positions, and 32 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 91
2% less funds holding
Funds holding: 265 → 259 (-6)
12% less call options, than puts
Call options by funds: $12.4M | Put options by funds: $14M
16% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 32
16% less capital invested
Capital invested by funds: $2.97B → $2.5B (-$475M)
50% less funds holding in top 10
Funds holding in top 10: 14 → 7 (-7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$111M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$25.9M |
| 3 |
Goldman Sachs
New York
|
+$22.3M |
| 4 |
O
OppenheimerFunds
New York
|
+$21.6M |
| 5 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
+$17.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$55.2M |
| 2 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$34.6M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$34.1M |
| 4 |
William Blair Investment Management
Chicago,
Illinois
|
-$32.1M |
| 5 |
DMK
David M. Knott
|
-$23.7M |
LGND Hedge Fund Activity: Q3 2016 in Review
259 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q3 2016, worth a combined $2.5B — down 16% from $2.97B a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of LGND and 27 opened new positions — a net loss of 5 holders — while 91 trimmed existing stakes and 109 added.
The largest buyer was Victory Capital Management, adding an estimated $111M. The largest seller was 1832 Asset Management, exiting entirely with an estimated $55.2M sold.
- 259 institutional investors held Ligand Pharmaceuticals (LGND) as of Q3 2016, down from 265 in Q2 2016.
- Funds reported $2.5B of Ligand Pharmaceuticals stock for Q3 2016, down 16% quarter-over-quarter.
- 27 funds opened new Ligand Pharmaceuticals positions in Q3 2016 and 32 closed out, a net change of -5 holders.
- The largest Ligand Pharmaceuticals buyer in Q3 2016 was Victory Capital Management, an estimated $111M added.
- The largest Ligand Pharmaceuticals seller in Q3 2016 was 1832 Asset Management, an estimated $55.2M sold.
Based on aggregated 13F filings for Q3 2016.